First bapi; now neuroscience puts stem cells on trial in autism
This article was originally published in Scrip
Researchers at Sutter Neuroscience Institute in Sacramento, California will run a first-of-its-kind US FDA-endorsed Phase II clinical trial in which autistic children between the ages of 2 and 7 will be treated with stem cells derived from their own umbilical cord blood to see if the therapy improves their language skills and behavior.
You may also be interested in...
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.